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The ability of the 3A protein of coxsackievirus B (CVB) to inhibit protein secretion was investigated for this
study. Here we show that the ectopic expression of CVB 3A blocked the transport of both the glycoprotein of
vesicular stomatitis virus, a membrane-bound secretory marker, and the alpha-1 protease inhibitor, a luminal
secretory protein, at a step between the endoplasmic reticulum (ER) and the Golgi complex. CVB 3A contains
a conserved proline-rich region in its N terminus. The importance of this proline-rich region was investigated
by introducing Pro-to-Ala substitutions. The mutation of Pro19 completely abolished the ability of 3A to inhibit
ER-to-Golgi transport. The mutation of Pro14, Pro17, or Pro20 also impaired this ability, but to a lesser extent.
The mutation of Pro18 had no effect. We also investigated the possible importance of this proline-rich region
for the function of 3A in viral RNA replication. To this end, we introduced the Pro-to-Ala mutations into an
infectious cDNA clone of CVB3. The transfection of cells with in vitro-transcribed RNAs of these clones gave
rise to mutant viruses that replicated with wild-type characteristics. We concluded that the proline-rich region
in CVB 3A is required for its ability to inhibit ER-to-Golgi transport, but not for its function in viral RNA
replication. The functional relevance of the proline-rich region is discussed in light of the proposed structural
model of 3A.
Enteroviruses (poliovirus, coxsackievirus, echovirus, and
several unnamed viruses) are small viruses that contain a
7.5-kb single-stranded RNA genome with positive polarity.
The genomic RNA harbors one large open reading frame that
encodes the viral polyprotein. This polyprotein is proteolyti-
cally processed by virally encoded proteases into the individual
capsid proteins and the nonstructural replication proteins
(2Apro, 2B, 2C, 3A, 3B, 3Cpro, and 3Dpol) as well as the rela-
tively stable precursor proteins 2BC, 3AB, and 3CDpro (22,
33). Replication of the viral RNA (vRNA) takes place in rep-
lication complexes in conjunction with secretory pathway-de-
rived membrane vesicles that accumulate in the cytoplasm of
the infected cell (2, 24). Enteroviruses are nonenveloped, cy-
tolytic viruses that do not rely on an intact secretory pathway to
release their virus progeny. Instead, poliovirus (PV) has been
shown to induce a general blockage of protein secretion (8).
Through the individual expression of the different nonstruc-
tural proteins of PV, Doedens and Kirkegaard have shown that
proteins 2B and 3A are each sufficient to inhibit transport
through the secretory pathway (8). The step blocked by the 2B
protein is presently unknown. The expression of the PV 3A
protein resulted in the accumulation in the ER of both the G
protein of vesicular stomatitis virus (VSVG) and the alpha-1
protease inhibitor (A1PI) (7, 8). Moreover, the inhibition of
ER-to-Golgi transport by PV 3A was shown to result in a
reduced secretion of cytokines and interleukins (6), a down-
regulation of major histocompatibility complex class I (MHC
I)-dependent antigen presentation (3), and resistance to tumor
necrosis factor alpha (TNF-)-induced apoptosis (by elimina-
tion of the TNF receptor from the cell surface) (19). These
findings represent unique examples of the evasion of both
innate and acquired immune responses as well as the extrinsic
apoptotic pathway by viral interference with secretory pathway
trafficking. The mechanism by which the 3A protein inhibits
secretory transport is as yet unknown.
In addition to its function in manipulating intracellular pro-
tein transport, the enterovirus 3A protein is involved in mul-
tiple steps in the process of vRNA replication. The 3A protein
is a small hydrophobic protein (87 to 89 amino acids [aa]) that
contains a C-terminal hydrophobic anchor which is responsible
for its membrane association (29). Several studies have shown
that mutations in 3A give rise to defects in vRNA synthesis (1,
10, 12, 35). The membrane-bound precursor 3AB is most likely
the donor of VPg (i.e., 3B), the peptide that serves as the
primer for vRNA synthesis, to the membranous replication
complex (21). Moreover, 3AB serves as a cofactor for the
binding of 3CD to the 5 and 3 termini of the RNA genome
(11), the polymerase activity of 3Dpol (16, 20), and the auto-
catalytic processing of 3CDpro to 3Cpro and 3Dpol (18).
For this study, we investigated whether the function of the
enterovirus 3A proteins in interfering with endoplasmic retic-
ulum (ER)-to-Golgi transport is conserved in the closely re-
lated coxsackievirus B (CVB). Expression of the CVB3 3A
protein was indeed sufficient to inhibit ER-to-Golgi transport.
* Corresponding author. Mailing address: Department of Medical
Microbiology, Nijmegen Center for Molecular Life Sciences, Univer-
sity Medical Center Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The
Netherlands. Phone: (31) 24 3617574. Fax: (31) 24 3540216. E-mail:
f.vankuppeveld@ncmls.ru.nl.
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All enterovirus 3A proteins contain a proline-rich region in
their N termini. The biological significance of this proline-rich
region, which may be involved in protein-protein interactions,
was investigated by the individual expression of CVB3 3A
mutants and the introduction of these mutations into an infec-
tious cDNA clone of CVB3. Our results indicate that the
integrity of this proline-rich region is required for the inhibi-
tion of ER-to-Golgi transport by the CVB3 3A protein, but not
for its functions in vRNA replication.
MATERIALS AND METHODS
Cells and viruses. Buffalo green monkey (BGM) kidney cells were grown in
minimal essential medium (MEM) (Gibco) supplemented with 10% fetal bovine
serum. COS-1 cells were grown in Dulbecco’s modified Eagle’s medium (Gibco)
supplemented with 10% fetal bovine serum. Cells were grown at 37°C in a 5%
CO2 incubator. All viruses used for this study were recombinant CVB3 viruses
obtained by the transfection of T7 RNA polymerase-generated runoff RNA
transcripts from the infectious cDNA clones described below. Virus yields were
determined by end-point titration as described previously (30). Virus titers were
calculated and expressed as 50% tissue culture infective dose (TCID50) values
(23).
Plasmids. (i) p53CB3/T7. The CVB3 infectious cDNA clone used for this
study was p53CB3/T7, which contains a full-length cDNA of CVB3 (strain
Nancy) behind a T7 RNA polymerase promoter. This cDNA clone was con-
structed by removing the nonviral nucleotides between the T7 promoter and the
5 end of the CVB3 genome from plasmid pCB3/T7 (14). Furthermore, an MluI
site was introduced downstream of the 3 end of the CVB3 genome to ensure
that in vitro-transcribed RNAs did not contain nonviral nucleotides at their 3
ends, resulting in increased infectivity of the RNA transcripts (data not shown).
(ii) p53CB3-LUC. Plasmid p53CB3-LUC, which contains the firefly luciferase
gene in place of the P1 capsid coding region, was derived from pCB3-LUC (30)
and contains the same deletion of nonviral nucleotides at the 5 and 3 termini
as p53CB3/T7.
(iii) pVSVG-GFP. The plasmid pVSVG-GFP (28), which encodes the ts045
VSVG protein fused to enhanced green fluorescent protein (EGFP) at its C
terminus, was kindly provided by P. Keller and K. Simons (Max Planck Institute
of Molecular Biology and Genetics, Dresden, Germany).
(iv) p3A. For construction of the p3A plasmid, the 3A coding sequence was
amplified by use of a forward primer that introduced a SalI restriction site and
a start codon preceded by a Kozak sequence (p120-4, 5-GGG GGG TCG ACC
ATG GGA CCA CCA GTA TAC AGA-3 [the SalI site is underlined]) and a
reverse primer that introduced a stop codon followed by a BamHI restriction site
(p120-5, 5-GGG GGG GGA TCC CTA TTG AAA ACC CGC AAA GAG-3
[the BamHI site is underlined]). The PCR product was cloned into pEGFP-C3
(Clontech) from which the EGFP coding region had been deleted.
(v) pC-A1PI-EYFP-S-EGFP-3A. The plasmid pCMS-EGFP (Clontech) was
used to express A1PI and 3A from a single plasmid. The pCMS-EGFP plasmid
contains two promoters, namely, a cytomegalovirus (CMV) promoter followed
by a multiple cloning site and a simian virus 40 (SV40) promoter followed by the
EGFP coding sequence. The secretory marker A1PI, with enhanced yellow
fluorescent protein (EYFP) at its C terminus, was cloned into the multiple
cloning site behind the CMV promoter by the use of EcoRI and NotI. The EGFP
coding sequence behind the SV40 promoter was replaced with 3A (wild type or
mutant) N-terminally fused to EGFP by the use of AgeI and BclI. The fusion of
EGFP to the N terminus of 3A did not affect its protein secretion inhibition
function (data not shown).
(vi) pPV5NC-A1PI-EYFP. For construction of the pPV5NC-A1PI-EYFP
plasmid, the 5 noncoding region of PV fused to the coding sequence for the
secretory marker A1PI was removed from pLink-2B (8) by the use of SmaI and
EcoRI and then cloned into pEGFP-C1 (Clontech) by the use of Ecl136III and
EcoRI. The A1PI coding sequence was replaced with the coding sequence for
A1PI-EYFP by removing A1PI by the use of EcoRV and SmaI and then cloning
in the A1PI-EYFP fragment cut with EcoRV and HpaI.
Mammalian two-hybrid plasmids. The pACT, pBIND, and pG5luc plasmids
were obtained from the Checkmate mammalian two-hybrid system (Promega).
For the construction of pACT-3A and pBIND-3A, the 3A coding sequence was
cloned into the BamHI and EcoRV sites of the pACT and pBIND plasmids. To
obtain pACT and pBIND-3A mutant plasmids, we replaced the wild-type 3A
sequence with mutant 3A sequences by using the enzymes Bst1107I and BamHI.
DNA transfections. BGM cell monolayers were grown in 6-well plates (for
A1PI secretion assays or Western blot analysis) or on coverslips in 24-well plates
(for microscopic purposes) to subconfluence and then transfected with 2 g of
plasmid DNA per well of a 6-well plate or with 0.5 g of plasmid DNA per well
of a 24-well plate. COS cell monolayers were grown in 24-well plates to subcon-
fluence and then transfected with 0.75 g of plasmid DNA (see below). Trans-
fections were performed by use of the FuGENE 6 reagent (Roche) according to
the manufacturer’s instructions. Cells were grown at 37°C until further analysis,
unless otherwise stated.
VSVG trafficking. The subcellular localization of VSVG-GFP was determined
as described previously (5). Briefly, BGM cells expressing either VSVG-GFP
alone or VSVG-GFP together with 3A were incubated at 40°C. After a temper-
ature shift to 32°C, the cells were fixed, stained, and analyzed by confocal laser
scanning microscopy (CLSM) under a TCS NT microscope (Leica Lasertechnik
GmbH, Heidelberg, Germany). Rabbit polyclonal anti-calreticulin was obtained
from Sigma-Aldrich. Mouse monoclonal anti-GM130 was obtained from BD.
Alexa fluor 594 goat anti-rabbit immunoglobulin G and Alexa fluor 594 goat
anti-mouse immunoglobulin G were obtained from Molecular Probes. Primary
antibodies were diluted 1:200, and conjugates were diluted 1:500.
A1PI secretion assay. BGM cells grown in six-well plates were transfected with
plasmid DNAs, and 20 h after transfection, were washed with phosphate-buff-
ered saline (PBS) and incubated in MEM lacking methionine (Sigma) for 30 min
at 37°C. Proteins were pulse labeled with [35S]methionine (50 Ci/well) for 30
min at 37°C and then washed twice with PBS, after which 800 l of fresh
serum-free MEM was added. After a 2-h chase, the medium was collected and
adjusted to 1 lysis buffer by the addition of 200 l of 5 lysis buffer (250 mM
Tris [pH 7.4], 750 mM NaCl, 5 mM EDTA, 5% Nonidet P-40, 0.25% sodium
dodecyl sulfate [SDS]). The cells were washed twice with PBS and then lysed in
1 ml of lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1%
Nonidet P-40, 0.05% SDS). An anti-EGFP rabbit polyclonal antiserum (1:1,000)
was added to the cell lysate and culture medium, and the mixtures were incu-
bated at 4°C for 16 h. Antibody-protein complexes were collected by the use of
protein A-Sepharose (Amersham Biosciences) for 1.5 h, washed twice with
dilution buffer (0.01 M Tris [pH 8.0], 0.14 M NaCl, 0.1% bovine serum albumin,
0.1% Triton X-100), once with TSA (0.01 M Tris [pH 8.0], 0.14 M NaCl), and
once with 0.05 M Tris (pH 6.8), and then precipitated. The samples were
resuspended in 25 l of Laemmli sample buffer, boiled for 5 min, and analyzed
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The amounts of ra-
diolabeled A1PI-EYFP in the cell fraction and the medium fraction were quan-
tified by use of a phosphorimaging device (Bio-Rad Multi-Analyst, version 1.0.1).
Site-directed mutagenesis. In vitro mutagenesis was performed with single-
stranded DNAs generated from a subgenomic pALTER phagemid construct
containing the XhoI (nucleotide [nt] 2014) to SalI (nt 7438) fragment of CVB3
by use of the Altered Sites in vitro mutagenesis system according to the manu-
facturer’s recommendations (Promega). The following synthetic oligonucleotides
were used to introduce site-specific mutations (as well as restriction sites, which
are underlined, to allow the rapid identification of mutants): primer p388-1,
5-GAG CAG GTC CGC AAT GGC GGG CGC TGC AGC TGT CTC TGG
TGC AAC GCT AAT-3 (P17A/P18A/P19A mutations, PvuII site); primer p388-
12, 5-CGG TGG TGG TGT CTC AGC TGC AAC GCT AAT TTT-3 (P14A
mutation, PvuII site); primer p388-7, 5-CAG GTC CGC AAT GGC GGG CGG
TGG CGC CGT CTC TGG TGC AAC GCT AAT TTT-3 (P17A mutation,
NarI site); primer p388-8, 5-GAG CAG GTC CGC AAT GGC GGG CGG
CGC CGG TGT CTC TGG TGC AAC GCT AAT-3 (P18A mutation, NarI
site); primer p388-9, 5-TTT GAG CAG GTC CGC AAT GGC GGG CGC
CGG TGG TGT CTC TGG TGC AAC GCT-3 (P19A mutation, NarI site);
primer p388-10, 5-CGA TTT GAG CAG GTC CGC AAT GGC CGC GGG
TGG TGG TGT CTC TGG TGC AAC-3 (P20A mutation, SacII site); primer
p388-11, 5-CAC AGC CTC ACA GTC TAC CGA TTT GAG CAG GTC CGC
AAT GGC GGG CGC TGC AGC TGT CTC TGG TGC AAC GCT AAT-3
(P17A/P18A/P19A/S31C mutations, PvuII site). The nucleotide sequences of the
mutant pALTER clones were verified by sequence analysis. The 3A mutations
were introduced into the p53CB3/T7 plasmid by the use of unique BssHII (nt
4242) and BstEII (nt 6263) sites. The mutant cDNAs were used as templates to
amplify mutant 3A sequences by use of a forward primer introducing a BamHI
site (p120-3, 5-GAG GCA CGG ATC CAG GGA CCA CCA GTA TAC-3 [the
BamHI site is underlined]) and a reverse primer (p388-6, 5-GAG GGT GGA
GTT GGT CTC CGG AAC CAA CCA TCC-3) that anneals downstream of the
internal ScaI site in the 3A coding sequence. The PCR products were cut with the
restriction enzymes BamHI and ScaI and cloned into pEGFP-3A cut with BglII
and ScaI to yield the pEGFP-3A mutant plasmids.
Transfection of cells with RNA transcripts. Plasmids were linearized with
MluI, purified, and transcribed in vitro by T7 RNA polymerase as described
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previously (30). The RNA transcripts were checked by agarose gel electrophore-
sis. BGM monolayer cells grown to subconfluence in 25-cm2 flasks were trans-
fected with 2.5 g of RNA transcripts by the DEAE-dextran method as described
previously (30). After transfection, the cells were grown at 37°C. When virus
growth was observed, the cultures were incubated until the cytopathic effect
(CPE) was complete. In cases in which no CPE was observed after 5 days, the
cultures were subjected to three successive cycles of freezing and thawing, and
200 l was passaged onto fresh BGM monolayer cells, which were grown at 37°C
for another 5 days.
Sequence analysis of viral RNA. RNAs were isolated from virus suspensions
and reverse transcribed as described previously (30). The 3A coding region was
amplified by PCRs with SuperTaq DNA polymerase (HT Biotechnology), and
the sequences were analyzed.
Single-cycle growth analysis. Confluent BGM monolayer cells were infected
with virus at a multiplicity of infection (MOI) of 1 TCID50 for 30 min at room
temperature. The cells were washed three times with PBS, supplied with MEM,
and grown at 37°C. At the indicated times, the cells were disrupted by three
cycles of freezing and thawing, and the virus titers were determined by end-point
titration.
Analysis of viral RNA synthesis. BGM cell monolayers were transfected with
1 g of T7 RNA polymerase-generated RNA transcripts from MluI-linearized
p53CB3/T7-LUC plasmids as described above. At the indicated times posttrans-
fection, the cells were lysed and luciferase activities was assayed as described
previously (30).
Calculations. Data are presented as mean values  standard errors of the
means (SEM). Differences were tested for significance by analysis of variance
(least significant difference [LSD]).
Western blot analysis. BGM cells grown in six-well plates were transfected
with pC-A1PI-EYFP-S-EGFP-3A plasmids (wild type or mutant). At 24 h post-
transfection, the cells were lysed in 1 lysis buffer (50 mM Tris [pH 7.4], 150 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.05% SDS). Samples were run in an
SDS–12.5% polyacrylamide gel and transferred to a nitrocellulose membrane
(Bio-Rad). EGFP fusion proteins were stained with an anti-EGFP polyclonal
antiserum (diluted 1:10,000) and peroxidase-conjugated goat anti-rabbit immu-
noglobulins (diluted 1:5,000) and visualized with the Lumi-Lightplus Western
blotting substrate (Roche Molecular Biochemicals) according to the manufac-
turer’s instructions.
Mammalian two-hybrid analysis. COS cells grown in 24-well plates were
transfected with a total of 0.75 g of plasmid DNA (1:1:1 mix of the pACT,
pBIND, and pG5luc plasmids). At 48 h posttransfection, the cells were lysed, and
both the firefly luciferase and Renilla luciferase enzyme activities were measured
from the same cell lysate by use of a dual-luciferase reporter assay system
(Promega) as described previously (4). An analysis of the Renilla luciferase
activities, encoded by the pBIND plasmid and allowing monitoring of the trans-
fection efficiency, revealed no gross differences in efficiencies of transfection
among the different samples.
RESULTS
Inhibition of ER-to-Golgi transport by CVB3 and 3A expres-
sion. To monitor secretory pathway trafficking, we made use of
a GFP fusion of the temperature-sensitive ts045 mutant of
VSVG, a well-known membrane-bound secretory marker
(VSVG-GFP). Figure 1A shows that at the nonpermissive tem-
perature (40°C), VSVG-GFP was improperly folded and, as a
consequence, retained in the ER (as indicated by its colocal-
ization with calreticulin, an ER protein). Upon shifting the
temperature to the permissive temperature (32°C), the protein
was correctly folded and transported out of the ER. After 45
min, the majority of the protein was found at the Golgi com-
plex (as indicated by its colocalization with GM130, a cis-Golgi
protein) (Fig. 1B). After 120 min, the protein was localized
mostly at the plasma membrane (Fig. 1C).
To investigate whether CVB3 inhibits vesicular trafficking,
we transfected BGM cells with the VSVG-GFP expression
plasmid, incubated them at 40°C, and then infected them with
CVB3 at an MOI of 50. The infected cells were further incu-
bated at 40°C and then shifted to 32°C (for 120 min) at 1-h
time intervals between 0 and 5 h postinfection (p.i.). The cells
were fixed and stained, and VSVG-GFP localization was ana-
lyzed by CLSM. In infected cells that were kept at 40°C,
VSVG-GFP was retained in the ER (Fig. 1D). In infected cells
that were shifted to 32°C at 0, 1, 2, or 3 h p.i., VSVG-GFP was
mainly localized at the plasma membrane (similar to the case
shown in Fig. 1C). In cells that were shifted to 32°C at 4 or 5 h
p.i., VSVG-GFP was found to accumulate in both the ER (Fig.
1E) and a dispersed post-ER compartment that also contained
the cis-Golgi marker (Fig. 1F). Together, these results suggest
that in CVB3-infected cells, protein transport is blocked from
about 4 h p.i. at a step between the ER and the Golgi.
Next, we tested whether expression of the CVB3 3A protein
alone was sufficient to inhibit ER-to-Golgi transport. BGM
cells were cotransfected with VSVG-GFP and a 3A expression
plasmid (at a 1:3 ratio to optimize the cotransfection effi-
ciency). The cells were incubated at 40°C for 20 h (Fig. 1G) and
then shifted to 32°C for 120 min. Figures 1H and I show that
in cells cotransfected with VSVG-GFP and 3A, VSVG was
mainly retained in the ER (Fig. 1H) and in a dispersed
post-ER compartment that also contained the cis-Golgi
marker (Fig. 1I), which was more or less similar to the case for
infected cells.
In order to quantify the inhibitory effects of CVB3 infection
and 3A expression on protein secretion, we made use of the
reporter protein A1PI, a secreted soluble glycoprotein. In
pulse-chase experiments, the level of A1PI secretion can be
determined by measuring the percentages of reporter protein
in the cell and medium fractions. For this study, a fusion
protein of A1PI and EYFP was used because the A1PI protein
was found to migrate to the same position as a nonspecific
protein band in BGM cell lysates (data not shown). Figure 2A
shows that the A1PI-EYFP fusion protein, which was labeled
for a 30-min pulse period and immunoprecipitated with anti-
EGFP, was efficiently secreted into the medium during a 2-h
chase period.
The inhibitory effect of CVB3 infection on protein secretion
was determined at various times p.i. Because enterovirus in-
fection shuts off cap-dependent translation (9), a plasmid was
used that contained the A1PI coding sequence behind the PV
5 noncoding region. Cells transfected with this construct were
infected with CVB3 (MOI 50), pulse labeled for 30 min with
[35S]methionine at 2, 4, or 6 h p.i., and subsequently chased for
2 h in the presence of unlabeled methionine. In cells labeled at
2 h p.i. (i.e., chased between 2.5 and 4.5 h p.i.), the majority of
A1PI was secreted into the medium (Fig. 2A). In cells labeled
at 4 or 6 h p.i. (i.e., chased between 4.5 and 6.5 h p.i. and
between 6.5 and 8.5 h p.i., respectively), however, only a small
amount of A1PI was observed in the medium fraction, whereas
a large amount of A1PI was retained in the cell. The amount
of A1PI in the medium fraction was determined as the per-
centage of the total amount of A1PI and compared to that of
control cells (for which the value was normalized to 100%
A1PI secretion). The average results of three independent
experiments are shown in Fig. 2B. The results demonstrate
that CVB3 infection inhibited reporter protein secretion to
approximately 30% compared to control cells from about 4 h
p.i.
To quantify the inhibitory effect of 3A on protein secretion,
we coexpressed the 3A protein (behind an SV40 promoter)
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and the A1PI secretion marker (behind a CMV promoter)
from a single plasmid. The 3A protein was expressed as an
EGFP-3A fusion protein (the fusion of EGFP to the N termi-
nus of 3A did not affect its protein secretion inhibition function
[data not shown]). As a control, a plasmid was constructed that
contained the EGFP sequence behind the SV40 promoter.
Western blot analysis showed that both proteins were effi-
ciently expressed (Fig. 2C). Figure 2D shows that the expres-
sion of the 3A protein resulted in a severely reduced amount of
labeled reporter protein in the medium fraction. A quantita-
tive analysis of A1PI secretion in three independent experi-
ments showed that 3A expression inhibited reporter protein
secretion to approximately 25% of that of control cells (Fig.
2E) (the percentage of A1PI secretion was calculated as de-
scribed above).
Importance of proline-rich region in 3A for inhibition of
ER-to-Golgi transport. The enterovirus and rhinovirus 3A pro-
teins are characterized by the presence of a proline-rich region
in the N terminus (Fig. 3). This proline-rich region is located at
aa 17 to 19 (numbering refers to the CVB3 3A protein). Pro17
and Pro19 are present in all 63 enterovirus and rhinovirus 3A
proteins that have been sequenced to date (except for entero-
virus [EV] type 71). Pro18 is present in nearly all enteroviruses
and rhinoviruses (except for coxsackievirus A16 [CVA16],
CVA24, EV70, and EV71). All human enterovirus group B
(HEV-B) members (which include all CVB types, all echovi-
FIG. 2. CVB3 infection (MOI of 50) and expression of the 3A protein inhibit A1PI secretion. BGM cells were transfected with A1PI expression
constructs. Twenty hours after transfection, the cells were starved of methionine for 30 min, labeled with [35S]methionine for 30 min, and then
chased for 2 h. Cell (C) and medium (M) fractions were collected and analyzed for the amount of labeled reporter protein by immunoprecipitation
with an anti-EGFP antiserum, SDS-PAGE, and phosphorimaging. (A) Cells transfected with a plasmid containing A1PI behind the PV noncoding
region were infected and subjected to pulse-chase analysis at 2, 4, and 6 h p.i. The differences in migration between A1PI in the medium and cell
fractions were due to differences in the glycosylation state (endoglycosidase F treatment resulted in faster migration of A1PI in both the medium
and cell fractions [data not shown]). (B) Average secretion (means standard errors of the means [SEM]) of three independent experiments. A1PI
secretion was calculated as the percentage of A1PI secretion in uninfected control cells, which was normalized to 100%. (C to E) BGM cells were
transfected with constructs expressing either EGFP (3A) or EGFP-3A (3A) from an SV40 promoter and the A1PI-EYFP protein from a
cytomegalovirus promoter. (C) Western blot analysis of EGFP and EGFP-3A expression. (D) Analysis of A1PI secretion. (E) Average secretion
(means SEM) of three independent experiments. A1PI secretion was calculated as the percentage of A1PI secretion in EGFP-expressing control
cells, which was normalized to 100%.
FIG. 1. CVB3 infection and expression of the 3A protein inhibit VSVG-GFP trafficking. BGM cells were transfected with a construct coding
for the GFP-tagged ts045 temperature-sensitive mutant of the VSVG protein, either alone or together with 3A, and grown at 40°C for 20 h. (A
to C) Control cells. In control cells, VSVG was improperly folded at 40°C, and as a consequence, was retained in the ER, as shown by its
colocalization with calreticulin (merged picture on the right in panel A). Upon shifting to the permissive temperature (32°C), the VSVG-GFP
protein was correctly folded and transported out of the ER. VSVG could be observed in the Golgi complex after 45 min, as shown by its
colocalization with GM130, a cis-Golgi marker (B), and at the plasma membrane after 120 min (C). (D to F) Cells infected with CVB3 (MOI of
50) for 5 h at 40°C. At 40°C, VSVG was retained in the ER (D). Upon shifting to 32°C for 120 min, VSVG could be found in the ER (E) and
a post-ER compartment that also contained the cis-Golgi marker (F). (G to H) 3A-expressing cells. VSVG was retained in the ER at 40°C (G),
whereas it was observed in the ER (H) and a post-ER compartment that also contained the cis-Golgi marker (I) when shifted to 32°C for 120 min.
Bar  10 m.
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ruses, some CVA types, and several unassigned EVs) contain
additional Pro residues at positions 14 and 20.
Proline-rich regions are often involved in protein-protein
interactions (reviewed in reference 13). To investigate the
functional importance of the proline-rich region in the CVB3
3A protein, we constructed mutant 3A expression plasmids.
Since Pro17, Pro18, and Pro19 are the most conserved proline
residues, we first replaced these three residues simultaneously
with Ala residues (P17A/P18A/P19A). Figures 4A and B show
that this 3A mutant was no longer able to inhibit protein
secretion. This was not due to reduced expression of the mu-
tant protein, as it was expressed at a similar level as wild-type
3A (Fig. 4E). Moreover, in cells that coexpressed this mutant
3A protein and VSVG-GFP, we observed that VSVG accumu-
lated at the plasma membrane (data not shown). Thus, the
proline-rich region is required for the ability of 3A to inhibit
protein secretion.
To investigate the importance of the Pro residues individu-
ally, we constructed mutant 3A proteins in which single Pro
residues at positions 14, 17, 18, 19, and 20 were replaced with
Ala residues (mutations P14A, P17A, P18A, P19A, and P20A,
respectively). The P19A mutation completely abolished the
ability of 3A to inhibit A1PI secretion (to a similar extent as
the P17A/P18A/P19A mutant) (Fig. 4C and D). The P14A,
P17A, and P20A mutations also impaired the ability of 3A to
inhibit protein secretion, although to a lesser extent. The P18A
mutation had no effect on the secretion inhibition activity of
3A. Western blot analysis showed that all mutant 3A proteins
were efficiently expressed (Fig. 4E). Thus, the Pro residues at
positions 14, 17, 19, and 20, but not that at position 18, are
important for the ability of 3A to inhibit protein secretion.
Importance of proline-rich region in 3A for its function in
viral replication. To study the effect of 3A mutations on viral
RNA replication and virus growth, we introduced mutations
into an infectious cDNA clone of CVB3. For each mutation,
two p53CB3/T7 clones were tested, derived from two indepen-
dently generated site-directed mutagenesis clones. The effects
of the P17A/P18A/P19A, P14A, P17A, P18A, P19A, and P20A
mutations on virus viability were studied by the transfection of
BGM cells with RNA transcripts. The results obtained for the
P17A/P18A/P19A mutant are described below. Cells trans-
fected with RNA transcripts carrying single Pro mutations
exhibited complete CPE in all transfections (Fig. 5A). vRNAs
were isolated from these cell cultures, and the 3A coding
region was amplified by reverse transcription-PCR and then
sequenced. In all cases, the original mutations were retained in
the vRNAs, and no secondary amino acid replacements had
occurred. The mutant viruses were further characterized by
single-cycle growth analysis (Fig. 5B). Viruses carrying muta-
tions exhibited wild-type growth characteristics. This indicated
that the mutant 3A proteins were correctly folded. In conclu-
sion, mutation of the individual Pro residues had no effect on
viral replication.
Identification of a second-site suppressor mutation. Cells
transfected with RNA transcripts containing the P17A/P18A/
P19A mutations exhibited no CPE up to 5 days posttransfec-
tion. After passage to fresh BGM cells, CPE was observed in
only one of eight transfected cell cultures (Fig. 6A). A se-
quence analysis of the 3A coding region showed that the in-
troduced mutations were retained in the obtained virus but
that a second-site suppressor mutation, A3T, had occurred at
nt 5119. This nucleotide mutation resulted in a Ser-to-Cys
FIG. 3. Alignment of aa 14 to 20 of the enterovirus and rhinovirus 3A proteins. The genome organization of CVB3 is depicted. CVB3 contains
a single open reading frame flanked by a 5 and 3 nontranslated region (NTR) and a poly(A) tail. The four capsid proteins (VP1 to VP4) and
seven nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C, and 3D) are shown. The 3A protein of CVB3 is an 89-aa protein which contains a C-terminal
hydrophobic domain (aa 61 to 82). 3A contains several Pro residues (at positions 14 and 17 to 20) in its N terminus. An alignment of these residues
for all enteroviruses and rhinoviruses that have been sequenced to date is shown. The species names are shown in bold. HEV-B, human enterovirus
B; HEV-A, human enterovirus A; HEV-C, human enterovirus C; HEV-D, human enterovirus D; PV, poliovirus; HRV-A, human rhinovirus A;
HRV-B, human rhinovirus B; CVB, coxsackievirus B; ECHO(*), all echoviruses sequenced to date (i.e., echoviruses 1 to 7, 9, 11 to 21, 24 to 27,
and 29 to 33); CVA, coxsackievirus A; EV, enterovirus.
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substitution at aa 31 of the 3A protein. To demonstrate that
this amino acid change in 3A was indeed responsible for the
growth of this mutant virus, we introduced the P17A/P18A/
P19A/S31C mutations into the infectious cDNA clone. BGM
cells transfected with RNA transcripts of this mutant showed
CPE on all occasions. A sequence analysis of the 3A coding
regions of the resulting viruses showed that the introduced
mutations were retained in the vRNAs. Thus, a S31C mutation
can indeed rescue the defect in virus growth caused by the
P17A/P18A/P19A mutations. Single-cycle growth analysis
showed that the mutant virus exhibited a severe delay in virus
growth (Fig. 6B).
To investigate whether the quasi-infectious phenotype [a
definition that indicates that the mutation disrupts vRNA rep-
lication to such an extent that (pseudo)reversion mutations or
second-site suppressor mutations can arise but that no virus
progeny can be observed harboring the original mutation] of
the P17A/P18A/P19A mutant was due to a defect in polypro-
tein processing, we performed in vitro translation reactions
with RNA transcripts generated from the wild type and the
mutant cDNA clone. An analysis of the [35S]methionine-la-
beled translation products by SDS-PAGE showed no differ-
ences between the wild type and the mutant, arguing that it is
unlikely that the growth defect of the mutant was due to ab-
errant processing of the viral polyprotein (data not shown). To
investigate whether the primary defect occurred at the level of
vRNA replication, we introduced the P17A/P18A/P19A muta-
tions into p53CB3/T7-LUC, a subgenomic replicon that con-
tains the luciferase gene in place of the P1 coding region. BGM
cells were transfected with RNA transcripts of this clone, and
at 10 h posttransfection, the cells were lysed and luciferase
expression was analyzed. Transfected cells were grown in the
absence or presence of guanidine hydrochloride (GuHCl), an
inhibitor of enterovirus replication that is used to determine
luciferase levels in the absence of replication (under this con-
dition, luciferase production only reflects translation of the
transfected replicon RNA). Figure 6C shows that luciferase
production by replicons carrying the P17A/P18A/P19A mutant
was the same in the absence or presence of GuHCl and also
the same as that observed for wild-type replicons when repli-
cation was inhibited by GuHCl. However, replicons carrying
the P17A/P18A/P19A/S31C mutant showed an increase in lu-
ciferase production. These findings provide evidence that the
quasi-infectious phenotype of the P17A/P18A/P19A mutant
was due to a primary defect in vRNA replication.
We also investigated whether the second-site suppressor
mutation could rescue the effect of the P17A/P18A/P19A mu-
tant on protein secretion. To this end, we introduced the P17A/
P18A/P19A and S31C mutations into the 3A protein and
tested their effect on A1PI secretion as described above. The
P17A/P18A/P19A/S31C mutant caused a similar disruptive ef-
fect on the ability of 3A to inhibit A1PI secretion as the
FIG. 4. Proline-rich region is required for secretion inhibition by CVB3 3A. Cells were transfected with plasmids expressing the indicated 3A
mutant proteins from an SV40 promoter and the A1PI reporter protein from a cytomegalovirus promoter. Twenty hours after transfection, the
cells were labeled with [35S]methionine for 30 min and chased in the presence of unlabeled methionine for 2 h. Cell (C) and medium (M) fractions
were collected, immunoprecipitated with an anti-EGPF serum, analyzed by SDS-PAGE (A and C), and quantified by phosphorimaging (B and D).
The amount of secreted A1PI in the absence of 3A was normalized to 100%, and the ability of 3A and 3A mutants to secrete A1PI was calculated
as a percentage of the A1PI secretion in control cells without 3A. Values represent means  SEM of three independent experiments. a,
significantly different from A1PI secretion in control cells without 3A; b, significantly different from A1PI secretion in the presence of wild-type
3A (calculated by analysis of variance with LSD; P 	 0.05). (E) Western blot of EGFP-3A wild-type and mutant proteins.
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P17A/P18A/P19A mutant (Fig. 6D). Thus, the second-site sup-
pressor mutation S31C did not rescue the defect in protein
secretion inhibition caused by the P17A/P18A/P19A muta-
tions.
It has been suggested that the enterovirus 3A protein forms
a homodimer. Cross-linking and analytical ultracentrifugation
studies showed that the first 60 aa of the PV 3A protein form
a homodimer (26). Evidence for PV 3A homomultimerization
was also obtained by yeast two-hybrid analysis (34). The pos-
sibility was considered that the second-site suppressor muta-
tion S31C might restore 3A-3A interactions that were dis-
rupted by the P17A/P18A/P19A mutations. We investigated
homomultimerization reactions of CVB3 wild-type 3A and 3A
proteins carrying the P17A/P18A/P19A or P17A/P18A/P19A/
S31C mutations by use of a mammalian two-hybrid system (4).
To this end, we cloned the 3A sequences in the correct reading
frame into the expression plasmids pACT (which provides the
activation domain of herpes simplex virus type 1 VP16) and
pBIND (which provides the yeast Gal4 DNA binding domain).
COS cells were cotransfected with these two plasmids and with
the plasmid pG5luc, a reporter plasmid that contains five
GAL4 binding sites upstream of a minimal TATA box that
precedes the firefly luciferase gene. An analysis of the lucif-
erase activity showed that the wild-type CVB3 3A protein did
indeed form homomultimers (Fig. 6E). No multimerization
was observed with 3A carrying the P17A/P18A/P19A muta-
tions. No obvious increase in multimerization was observed
with 3A carrying mutation P17A/P18A/P19A/S31C.
DISCUSSION
In this study, we showed that CVB3 infection and expression
of the 3A protein alone interfere with protein secretion by
blocking ER-to-Golgi transport. Moreover, we demonstrated
that the proline-rich region in the N terminus of 3A is required
for this ability. Pro17, Pro18, and Pro19 are evolutionarily con-
served in nearly all enteroviruses and rhinoviruses. Of these
residues, Pro19 was found to be the most important for 3A to
inhibit protein secretion. Mutation of this residue almost com-
pletely abolished this activity. The mutation of Pro17, on the
other hand, was far less disruptive for the inhibitory activity of
3A. Mutation of this residue was even less disruptive than
mutations of the less-conserved Pro14 and Pro20 residues,
which are conserved in all HEV-B members (i.e., all CVBs and
echoviruses, some CVAs, and some unnamed enteroviruses)
but not in other enteroviruses and rhinoviruses. Remarkably,
the mutation of Pro18 had no notable effect.
The mechanism by which 3A inhibits protein secretion is still
unknown. Therefore, we can only speculate about a role of the
proline-rich region in the inhibition of protein secretion. Pro
residues can play an important role in protein-protein interac-
tions (reviewed in reference 32). We propose that the 3A
protein exerts its activity by tethering a cellular protein through
an interaction with its proline-rich region.
Two well-known protein interaction domains that interact
with Pro residues are Src homology 3 (SH3) and WW domains.
SH3 domains recognize proline-rich sequences containing the
core PXXP, where “X” denotes any amino acid. WW domains
bind ligands containing PPXY or PPLP core motifs, usually
flanked by additional Pro residues (13, 17). It seems unlikely,
however, that 3A interacts with proteins containing an SH3 or
a WW domain. When considering putative interaction do-
mains, one should take into account the fact that the Pro14 and
Pro20 residues are not conserved among all enteroviruses and
rhinoviruses. The 3A proteins of CVB3 and PV (which lacks
Pro14 and Pro20) most likely use identical mechanisms to in-
hibit protein secretion. Given the observation that a mutation
of Pro18 had little effect on this ability, these proteins most
likely only share Pro17 and Pro19 for their secretion inhibition
function. Therefore, alternative interaction domains or mech-
anisms should be considered.
Recently, the structure of the first 60 aa of the PV 3A
protein was determined by nuclear magnetic resonance spec-
troscopy (26). The PV 3A protein was found to form a classic
homodimer. Dimerization occurs through ionic interactions,
hydrogen bonds, and hydrophobic interactions between two
helices formed by aa 23 to 29 and aa 32 to 41. Figure 7 shows
the putative structure of the first 60 aa of CVB3, obtained by
molecular modeling of the published PV 3A structure. The
structure suggests that the proline-rich regions of two interact-
ing 3A proteins are oriented in such a way that they are con-
tiguous and thereby form a Pro platform. We suggest that this
Pro platform, rather than specific SH3 or WW binding do-
mains, may be the interaction domain responsible for the bind-
ing of a (still unknown) cellular protein.
The CVB3 3A protein inhibited protein secretion to an
FIG. 5. Proline-rich region is not important for CVB3 growth.
(A) Effect of the indicated 3A mutations on virus growth. Mutations
were introduced into the infectious cDNA clone p53CB3/T7. Copy
RNA transcripts were transfected into BGM cells and examined for
the ability to yield viruses. All mutations resulted in viable viruses
except the P17A/P18A/P19A mutations, which caused a quasi-infec-
tious (q.i.) phenotype. (B) Single-cycle growth analysis of mutant vi-
ruses. BGM cells were infected at an MOI of 1 and incubated at 37°C.
At 2, 4, 6, or 8 h postinfection, viruses were released from the infected
cells by three cycles of freezing and thawing. Virus titers were deter-
mined by titration on BGM cells and expressed in TCID50 values.
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extent similar to that previously described for the 3A protein of
the closely related PV (7). A PV mutant (mutant 3A-2) con-
taining a Ser insertion between 3A residues 14 and 15 (corre-
sponding to aa 15 and 16 in CVB3) was strongly impaired in
inhibiting A1PI secretion (7). The PV carrying this insertion
mutation showed a reduced ability to inhibit the presentation
of MHC I-antigen complexes (3) and to block the secretion of
cytokines and interleukins (6). The introduction of this muta-
tion into CVB 3A (i.e., a Ser insertion between residues 15 and
16) also interfered with the ability of 3A to inhibit A1PI se-
cretion (data not shown). The mutation disrupted this 3A
function to a similar extent as the P19A mutation. It is there-
fore reasonable to assume that CVB3 carrying Pro-to-Ala mu-
tations (in particular P19A) is also impaired in the ability to
suppress MHC I-antigen presentation and to block the secre-
tion of cytokines and interleukins.
Enterovirus genome replication takes place at secretory
pathway-derived membrane vesicles that accumulate in the
cytosol of the infected cell. The 2BC protein has been identi-
fied as playing a major role in the accumulation of these ves-
icles (2, 24, 25). It has been speculated that the 3A-induced
inhibition of ER-to-Golgi transport might also contribute to
the accumulation of the vesicles with which the viral replication
complexes are associated (27). However, in the present study,
we showed that viruses carrying mutations in 3A that inter-
fered with its ability to inhibit ER-to-Golgi transport replicated
with wild-type growth characteristics, arguing against a possi-
ble role of 3A in the accumulation of replication vesicles. It
FIG. 6. A second-site suppressor mutation in 3A rescues the effect of the P17A/P18A/P19A mutations. (A) Effect of the indicated 3A mutations
on virus growth. The P17A/P18A/P19A mutations resulted in a quasi-infectious (q.i.) phenotype and yielded virus in only one of eight transfected
cultures. A sequence analysis showed the presence of the second-site suppressor mutation S31C. The P17A/P18A/P19A/S31C mutant yielded virus
upon all transfections. (B) Effect of the P17A/P18A/P19A/S31C mutations on virus growth. Single-cycle growth analysis was performed as described
in the legend to Fig. 5. (C) Effect of P17A/P18A/P19A and P17A/P18A/P19A/S31C mutations on viral RNA replication. The mutations were
introduced into p53CB3-LUC, and transcripts from these replicons were transfected into BGM cells. The cells were grown for 10 h in the presence
() or absence () of 2 mM GuHCl, an inhibitor of enterovirus replication. Luciferase activities are depicted in light units (LU). (D) Effect of
P17A/P18A/P19A and P17A/P18A/P19A/S31C mutations on A1PI secretion. The analysis was performed as described in the legend to Fig. 4.
(E) Homomultimerization reactions of wild-type 3A and the 3A-P17A/P18A/P19A and 3A-P17A/P18A/P19A/S31C mutants expressed as fusion
proteins to the HSV VP16 activation domain or the yeast GAL4 DNA binding domain. COS cells were transfected with the indicated constructs
and assayed for firefly luciferase production at 48 h posttransfection. Dashes indicate the expression of unfused VP16 or GAL4 protein. LU, light
units.
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cannot be excluded that the 3A protein contributes to an ac-
cumulation of vesicles, but this activity does not seem to be
essential for viral RNA replication, at least not in vitro.
In contrast to the wild-type phenotype of viruses carrying the
single Pro-to-Ala mutations, the P17A/P18A/P19A mutant
yielded a quasi-infectious phenotype. Upon multiple RNA
transfections, only on one occasion was virus obtained. A se-
quence analysis of the viral RNA showed that a second-site
suppressor mutation at position 31 of 3A (S31C) had occurred.
This second-site suppressor mutation rescued a defect in 3A in
viral RNA replication, but not its ability to inhibit protein
secretion. Since the single Pro-to-Ala mutations did not affect
viral RNA replication, it can be hypothesized that the P17A/
P18A/P19A mutations interfere with the conformation of 3A
or its precursor 3AB and thereby with its function in vRNA
replication. Indeed, we found that the P17A/P18A/P19A mu-
tation interfered with 3A homomultimerization in a mamma-
lian two-hybrid system. This finding is remarkable because the
structural model predicts no important role for the proline-rich
region in dimerization. Together, these data are consistent
with the idea that the P17A/P18A/P19A mutation causes a
general disruption of the 3A structure. How the S31C suppres-
sor mutation, which is present in the loop between the two
-helices implicated in dimerization (Fig. 7), can (partially)
rescue the defect in vRNA replication imposed by the P17A/
P18A/P19A mutation remains to be established. Further re-
search is needed to establish the requirement of 3A dimeriza-
tion for its function in vRNA replication and its ability to
inhibit ER-to-Golgi trafficking.
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